Abstract | BACKGROUND: PROCEDURE: One hundred and twenty five eligible patients were enrolled. Induction was identical for both arms. Post induction patients were randomized to receive APO with vincristine every 3 weeks or a regimen that substituted vincristine with weekly vinblastine (APV). RESULTS: There was no difference between the patients randomized to the APO versus APV arms in either event free survival (EFS) or overall survival (OS) (three year EFS 74% vs. 79%, P = 0.68 and three years OS of 84% vs. 86%, P = 0.87, respectively). Patients in the APV arm required dose reduction secondary to myelosuppression and had a higher incidence of neutropenia as well as infection with neutropenia compared to those in the APO arm (P < 0.001, P = 0.019, respectively). CONCLUSIONS: Treatment with weekly vinblastine instead of every three week vincristine as part of multi-agent maintenance therapy did not result in improvement in EFS or OS. Weekly vinblastine was associated with increased toxicity. (ClinicalTrials.gov Identifier NCT00059839).
|
Authors | Sarah Alexander, Jacqueline M Kraveka, Sheila Weitzman, Eric Lowe, Lynette Smith, James C Lynch, Myron Chang, Marsha C Kinney, Sherrie L Perkins, Joseph Laver, Thomas G Gross, Howard Weinstein |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 61
Issue 12
Pg. 2236-42
(Dec 2014)
ISSN: 1545-5017 [Electronic] United States |
PMID | 25156886
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial)
|
Copyright | © 2014 Wiley Periodicals, Inc. |
Chemical References |
- Vincristine
- Vinblastine
- Doxorubicin
- Mercaptopurine
- Prednisone
- Methotrexate
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Child
- Child, Preschool
- Doxorubicin
(administration & dosage)
- Female
- Follow-Up Studies
- Humans
- Infant
- Lymphoma, Large-Cell, Anaplastic
(drug therapy, mortality, pathology)
- Male
- Mercaptopurine
(administration & dosage)
- Methotrexate
(administration & dosage)
- Neoplasm Staging
- Prednisone
(administration & dosage)
- Prognosis
- Survival Rate
- Vinblastine
(administration & dosage)
- Vincristine
(administration & dosage)
- Young Adult
|